Pharmaron: Fulfilling the “Green” and “Low-carbon” Mission and Striving to Improve Sustainability

HONG KONG, Dec 20, 2022 – (ACN Newswire) – Pharmaron (Stock Code: 300759.SZ/3759.HK) is a premier R&D service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities and established a broad spectrum of research, development and manufacturing service capabilities throughout the entire drug discovery, preclinical and clinical development process across multiple therapeutic modalities, including small molecules, biologics and CGT products. With around 17,000 employees, and operations in China, U.S., and U.K., Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China.

"Green" and "low carbon" have remained the keywords along Pharmaron's development. Pharmaron set it's first five-year environmental targets in 2016 and achieved reduction of water consumption and the energy consumption per RMB10,000 of output value by 25% and 20% in 2020, respectively, which showed solid results in energy savings and emissions reduction. In 2021, Pharmaron further developed the 2021-2025 Environmental Targets based on the characteristics of its industry and align with the United Nations (UN)'s advocacy for climate action, as well as the peak carbon emissions and carbon neutrality targets of the countries where it operates. Pharmaron will continue to taking concrete actions toward the targets and further improve its environmental management system, resource savings exercises, waste & pollutant reduction effort, and green facility upgrades. Moreover, Pharmaron will continuously promoting green chemistry practices and establishing more suitable and efficient processes to reduce waste and pollutants.

At the corporate level, Pharmaron incorporated ESG governance into the overall corporate governance and operations and is committed to continuously improving its ESG governance and management systems through updating the policies and systems, initiating targeted campaigns, increasing operational transparency, etc. According to its 2021 Environmental, Social and Governance Report, as the global COVID-19 pandemic continued, Pharmaron's team continues to be guided by its mission "to support its partners' success in discovery, development and commercialization of innovative medicines" and continue to develop its fully integrated end-to-end clinical service platform.

Pharmaron built a three-tiered ESG governance with clear responsibilities to ensure the effective implementation of its ESG strategies. In addition, Pharmaron place high emphasis on interactions and alignment of priorities with stakeholders on various ESG topics, through regular questionnaire surveys and interviews, to better address the expectations of different stakeholders.

Pharmaron provides its customers with high-quality, high value-added services and novel solutions. Its quality assurance system seamlessly manages the entire product lifecycle from customer acceptance through raw material procurement, R&D service execution, and quality inspection onto R&D product delivery and more; its complete set of information security management strategies served to protect information security and ensure the confidentiality, integrity, and availability of the information assets; its five-level intellectual property rights (IPR) protection system consisting of "Management Safeguard, Policy Safeguard, Legal Document Safeguard, Training Safeguard, and Technical Safeguard" was effective in delivering reinforced IPR protection. It remained committed to the "Honesty, Credibility, Mutual Benefit and Win-Win" principles when engaging with its suppliers. It managed and controlled environmental and social risks in the supply chain relating to core issues, such as business integrity, business information security, supply chain labor rights, and supply chain environmental protection. It implemented transparent procurement to maintain a fair environment for its prospective suppliers.

The research and development of new medicines are fundamental to human health and wellness. In the coming year, Pharmaron will, as always, fulfill its responsibilities for all stakeholders including the society, environment, investors/shareholders, employees, customers, supply chain, etc. It will follow its ESG commitments to being green, sustainable and transparent as well as strive to continuously improve economic, environmental and social sustainability.

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

LUI Che Woo Prize donates RMB 250 million to support the development of Shanghai Jiao Tong University Zhangjiang Science Park, The new campus is named Lui Che Woo Science Park

HONG KONG, Dec 20, 2022 – (ACN Newswire) – Dr Lui Che-woo, Chairman of K. Wah Group (the "Group") and the founder of LUI Che Woo Prize – Prize for World Civilization ("LUI Che Woo Prize"), has donated RMB 250 million through the LUI Che Woo Prize to support the development of Shanghai Jiao Tong University ("SJTU") Zhangjiang Science Park and contribute to national science and technology development. To thank Dr Lui for his generous donation, the new campus will be named Lui Che Woo Science Park. The agreement signing ceremony was held in Hong Kong today, guests including HKSAR Chief Executive John Lee who gave a video speech; former Chief Executive Carrie Lam, Executive Director of K. Wah International Holdings Limited ("KWIH") Alexander Lui, Executive Director of KWIH and member of board of trustees of SJTU Paddy Lui, Secretary of the CPC SJTU Committee Yang Zhen Bin; and Vice President of SJTU Zhang An Sheng. Professor Lin Zhong Qin, President of SJTU, and other university leaders participated in the ceremony via webcast. After the ceremony, Professor Ding Kui Ling, Executive Vice President of SJTU, Academician of the Chinese Academy of Sciences and Dean of the Zhangjiang Institute for Advanced Study, delivered a keynote speech on China's Forefront Science and Technology Development through a live webcast to promote the exchange of science and technology development and ties between Shanghai and Hong Kong.

A rendering of Lui Che Woo Science Park in completion.

1. Lui Che Woo Science Park Block 1: AI Biomedicine Centre, DNA Storage and Research Centre; 2. Block 2: Integrated Scientific Innovation Research Centre; 3. Block 3: AI Cybersecurity Innovation Centre; 4. Block 4: Frontiers Science Centre for Transformative Molecules, Future Material Creation Centre; 5. Block 5: Ultra-Fast Science Centre; 6. Science Park Complex; 7. Teacher and student dormitory; 8. Teacher and student dormitory; 9. The adjacent Shanghai Synchrotron Radiation Facility

Dr Lui Che-woo, Chairman of K. Wah Group and the founder of LUI Che Woo Prize – Prize for World Civilization (middle) and Yang Zhen Bin (2nd left), Secretary of the CPC SJTU Committee sign the donation agreement, accompanied by Alexander Lui (2nd right), Executive Director of K. Wah International Holdings Limited; Paddy Lui (1st right), Executive Director of K. Wah International Holdings Limited and member of board of trustees of SJTU; and Zhang An Sheng (1st left), Vice President of SJTU.

Dr Lui Che-woo, Chairman of K. Wah Group and the founder of LUI Che Woo Prize – Prize for World Civilization (1st row – 2nd right), Yang Zhen Bin (1st row – 2nd left), Secretary of the CPC Shanghai Jiao Tong University ("SJTU") Committee, former chief executive Carrie Lam (1st row – 1st right), Zhang An Sheng (1st row – 1st left), Vice President of SJTU, take a group photo with the representatives from the LUI Che Woo Prize, members of board of trustees, and representatives from the SJTU.

Dr Lui Che-woo, Chairman of K. Wah Group and the founder of LUI Che Woo Prize – Prize for World Civilization delivers a speech.

John Lee, HKSAR Chief Executive, gives a video speech

The agreement signing ceremony was webcast live at the lecture hall of the "Lui Che Woo Science Park" of Shanghai Jiao Tong University.

Nurture new generations of scientists with SJTU to benefit mankind through scientific research and development ("R&D")

SJTU is a well-known comprehensive university located in Shanghai. It plays a crucial role in the national innovation strategy and supports technological development, with a profound impact on the future of China and the wellbeing of people. In 2014, President Xi Jinping expressed hope of developing Shanghai into a technological innovation hub. The National Development and Reform Commission and the Ministry of Science and Technology then accelerated the construction of a technological innovation centre in the Zhangjiang area. Located in Zhangjiang, Lui Che Woo Science Park will be key for SJTU as it actively plays a part in constructing a national science centre in the area, and from which to build a world-class R&D base by promoting technological innovation and extensive integration with economic and social development, thus further strengthening China's international presence and influence in relevant fields.

Dr Lui Che-woo, Chairman of K. Wah Group and the founder of LUI Che Woo Prize – Prize for World Civilization said, "SJTU is recognised for being one of the premier education institutions in China. It is renowned both at home and abroad, and has the longest history – stretching more than 120 years. Moreover, it has nurtured countless talent with adherence to its motto of "Gratitude and Responsibility". I am looking forward to the development of Lui Che Woo Science Park as it gradually becomes an internationally influential technological innovation centre, creating synergies with large-scale national science facilities and pursuing new R&D breakthroughs with other science parks. This includes the Shanghai Synchrotron Radiation Facility ("SSRF") nearby, which is one of the world's top five synchrotron light source projects and is engaged in the creation of new materials from atomic and molecular structures that are the fundamental of science."

Yang Zhen Bin, Secretary of the CPC SJTU Committee, thanked Dr Lui for his generous support for the university, and said, "Dr Lui Che-woo selflessly promotes the advancement of mankind and encourages technological innovation through extraordinary wisdom. His assistance in the development of Lui Che Woo Science Park will boost the national technological innovation strategy and education development at SJTU. Lui Che Woo Science Park will lead SJTU as it integrates into the Zhangjiang Comprehensive National Science Centre and participates in the construction of a globally influential technological innovation centre. Through the steadfast attention of Dr Lui Che-woo and his family, we believe that Lui Che Woo Science Park will grow into an innovative platform for cross-disciplinary research; achieving major scientific breakthroughs, attracting top and innovative talent and utilising industrial technologies. "

Optimise R&D conditions to attract and train professionals and consolidate China's international position in the R&D field

As the primary technological innovation centre in Shanghai and a top national high-tech base, Zhangjiang Science Park possesses sizeable and comprehensive facilities, platforms, and superb institutes. Lui Che Woo Science Park is positioned as a world-class influential technological innovation centre, and is set to create a strong cluster effect with other large-scale national scientific facilities in the area. It is expected to promote the leapfrog development of multiple disciplines in China, build a cutting-edge interdisciplinary research platform, and become the centre for gathering top scientists.

Lui Che Woo Science Park covers a GFA of over 100,000 square meters, half of which is for R&D use. There are eight buildings in total, housing more than 1,200 researchers from various disciplines which includes approximately 600 researchers, postdoctoral fellows, and about 600 researchers with doctoral and master degrees. They will mainly focus on the R&D of health, biomedical engineering and new materials.

Seven centres and one platform support interdisciplinary scientific research

Lui Che Woo Science Park houses seven research centres, including the AI Biomedicine Centre, DNA Storage and Research Centre, Integrated Scientific Innovation Research Centre, AI Cybersecurity Innovation Centre, Frontiers Science Centre for Transformative Molecules, Future Materials Creation Centre and Ultra-Fast Science Centre. Upon completion, the park will facilitate the construction of the Zhangjiang Comprehensive National Science Centre and drive China's fundamental R&D and related industrial development in interdisciplinary fields, such as physics, materials, biology, medicine and network, and so on.

To facilitate collaboration among the seven research centres, the Lui Che Woo Science Park has built a public instrument platform, which currently has 65 sets of equipment worth a total of RMB137 million. It also boasts around 1,300 square meters of laboratory space, which will help further raise the standard of fundamental technologies, including element, organic molecule and molecular function analysis; providing greater and broader technical support for SJTU in terms of the detection and characterisation of such areas as organic chemistry, pharmacy, life science, medicine and material science. Furthermore, the instruments are available for teachers and students at SJTU to build a user-oriented training system. Technical training and exchanges will also be held regularly.

Collaborates with SSRF to realize research results at Frontiers Science Centre for Transformative Molecules ("FSCTM")

The Lui Che Woo Science Park is adjacent to SSRF, which has one of the world's top five synchrotron light source projects. The two parties have formed a strategic partnership and will cooperate in research into new molecules and materials. SSRF possesses operations that comparable to powerful "super X-ray machines" and "super microscopes", which can be used for researching in medicine, physics, science and so on.

With the support from SSRF, the FSCTM at Lui Che Woo Science Park has developed the ultra-fast in-situ characterization technology. Through molecular electricity catalysis, new substances or materials can be developed for applications in medicine, clean energy and green chemicals. In 2022, results from the research team at the centre have been published by top international academic journals, such as Nature and Science.

Enhances technological innovation and assists the country in implementing innovation-driven development strategies

Dr Lui shares President Xi Jinping's thoughts that "science and technology are having a profound impact on the future of the country as well as on people's wellbeing like never before". He believes that there is an urgency to strengthen technological innovation to help the country play a major role in implementing development strategies and accelerating the replacement of traditional strategies with new ones.

Having participated in philanthropy for nearly half a century, Dr Lui has been focusing on the support for education sector to align with the pace of national development. In particular, he is keen on supporting advanced scientific research and development in recent years, with the hope of contributing to the growth of the country. Dr Lui donated RMB120 million to the School of Life Sciences at Peking University in 2017 and RMB200 million to Tsinghua University in 2018 for the construction of two new blocks at the Biomedical Sciences Building, demonstrating his commitment to boosting life sciences development. Following these two donations, Dr Lui donated RMB250 million to SJTU to fund the construction of Lui Che Woo Science Park to support China's new and high-tech research development.

Dr Lui concluded, "I migrated to Hong Kong at the age of four and have established K. Wah Group for nearly seven decades. Having witnessed the achievements of our motherland and Hong Kong in the new century, I was buoyed to uphold the belief of 'giving back to society from which one has benefited'. Technology has been developing at a rocket pace and will serve as the lifeline to people and civilization in the future. I am honoured to support SJTU's establishment of Lui Che Woo Science Park, and I hope its cutting-edge facilities and talent will contribute to scientific research and development in Shanghai and across China. I believe that the collaboration and exchange with international scientific research institutions will also boost the stature of China's scientific research in the global arena."

About LUI Chi Woo Prize
Founded by Dr Lui Che-woo in 2015, the "LUI Che Woo Prize – Prize for World Civilisation" is an annual, first of its kind international cross-sector innovative award for advancing world civilisation and inspiring people to build a more harmonious world. It aims to recognise and honour individuals or organisations all over the world for outstanding contributions and encourages the continuation of that work in three objectives: sustainable development of the world, betterment of the welfare of mankind and promotion of positive life attitude and enhancement of positive energy.

For more details, please go to www.luiprize.org.

About K. Wah Group
K. Wah Group was founded in 1955 by Dr Lui Che-woo, who transformed the company into a multinational corporation. Core businesses include property development and investment, entertainment and leisure resorts, hospitality and construction materials. The Group has a business presence in Mainland China, Hong Kong, Macau, Southeast Asia and major cities in the US. The Group includes two Hong Kong-listed flagships: K. Wah International Holdings Limited ("KWIH"; HK stock code: 00173) and Galaxy Entertainment Group Limited ("GEG"; HK stock code: 00027 and a member of the Hang Seng Index) and over 200 subsidiaries, includes Stanford Hotels International and K. Wah Construction Materials Limited.

Website: http://www.kwah.com

Media Enquiries:

K. Wah Group
Helen Cheung Tel: (852) 2960 3739 Email: helencheung@kwah.com
Jenny Tse Tel: (852) 2960 3101 Email: jennytse@kwah.com
Andrey Leung Tel: (852) 2960 3364 Email: andreyleung@kwah.com
Fax: (852) 2811 9710

Lui Che Woo Prize – Prize for World Civilization
Brenda Kan Tel: (852) 2960 3791 Email: brendakan@luiprize.org

Strategic Financial Relations Limited
Iris Lee Tel: (852) 2864 4829 Email: iris.lee@sprg.com.hk
Shelly Cheng Tel: (852) 2864 4857 Email: shelly.cheng@sprg.com.hk

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Moonstake Partners with Unstoppable Domains for Simplified Crypto Transactions

SINGAPORE, Dec 20, 2022 – (ACN Newswire) – Moonstake is excited to announce we have become strategic partners with the leading multi-purpose blockchain domain solution Unstoppable Domains to simplify the crypto experience across the Web3 ecosystem. With the new integration, our users can now use a single "crypto username" to make transactions to others as well as applications and services supported by Unstoppable Domains. Conveniently send and receive Bitcoin, Ethereum, Cardano, and USDT cryptocurrencies using one simple custom "name" instead of juggling between multiple complicated crypto addresses.

With a single Unstoppable Domain name, make transactions of BTC, ETH, ADA, and USDT hassle-free on Moonstake Wallet. Instead of having to share multiple long, alphameric addresses to send and receive, you can just use a simplified, easily readable domain name. Unstoppable Domains are built on the Crypto Name Service (CNS) on Ethereum, issued as ERC-721 tokens that grant user irrevocable ownership of the domains they have created. This means that users are always in full control of their domain and assets and can manage their domain from any compatible wallet, exchange, marketplace, or any other Web3 applications that support this standard.

Mitsuru Tezuka, Founder at Moonstake, says: "We are thrilled to partner Unstoppable Domains to simplify crypto transactions for users worldwide. With the human-readable, customized domain name to replace long, complex crypto addresses, Moonstake hopes to improve the experience of crypto users by eliminating user error in your everyday crypto interactions. We are happy to be a strategic partner of the Unstoppable Domains ecosystem to help deliver a frictionless Web3 experience for global users while empowering you to always be in control of your assets."

Moonstake started the staking business in 2020 with the aim to create the largest staking network in Asia. Since then, we have developed the most user-friendly Web Wallet and Mobile Wallet (iOS / Android) with support for over 2000 cryptocurrencies. After a full-scale operation launched in August 2020, Moonstake's total staking assets have grown rapidly to reach $1 Billion, allowing Moonstake to become one of the top 10 staking providers globally. Currently, Moonstake supports 18 leading PoS assets including Cosmos, IRISnet, Ontology, Harmony, Tezos, Cardano, Qtum, Polkadot, Quras, Centrality, Orbs (Ethereum and Polygon), IOST, TRON, Shiden, FIO, Everscale, Oasisa and Solana.

Meanwhile, Unstoppable Domains enables seamless connection to Web3 through the use of blockchain domains. Purchasing your own Unstoppable Domain allows you to have a blockchain-connected web address that turns multiple crypto addresses into one human-readable name that can also connect with exchanges, marketplaces, and other Web3 applications. This greatly simplifies crypto interactions by eliminating user errors when handling many lengthy randomized public keys. The purchased Unstoppable Domain is also in your full control, as you can transfer, upload, and link it to any compatible services and platform, such as Moonstake.

Follow us on Twitter and Telegram for the latest updates on Moonstake news!

About Moonstake

Moonstake is the world's leading staking service provider that develops and operates decentralized wallet services for businesses and individuals. Since its launch in April 2020, Moonstake has partnered with 27 leading platform providers, including Cardano's constituent Emurgo, developer of the Polkadot-connected blockchain Astar Network Stake Technologies, and the TRON Network with over 50 million users. In May 2021, Moonstake further enhanced its corporate credibility by becoming a wholly owned subsidiary of OIO Holdings Limited, a company listed on the Singapore Stock Exchange. Using blockchain technology, Moonstake aims to progress toward a world where anyone can easily make use of highly secure and reliable digital asset management tools. https://www.moonstake.io/

About Moonstake's staking business

For the staking industry, which has grown into a 630-billion dollar market as of September 2021, Moonstake provides a decentralized staking service that does not require user deposits, and supports nodes around the world in addition to its own validator nodes. Moonstake currently supports the staking of 18 blockchains. With a total staking assets of 1.8 billion USD and a global user base, the company ranked third out of more than 10,000 providers worldwide in June of the same year.

About Unstoppable Domains

Founded in 2018, Unstoppable Domains is an NFT domain name provider and digital identity platform working to onboard the world onto Web3. Unstoppable Domains offers NFT domains minted on the blockchain that give people full ownership and control of their digital identity, with no renewal fees. With Unstoppable Domains, people can replace lengthy alphanumeric crypto wallet addresses with a human-readable name and log into and transact with more than 200 apps, wallets, exchanges and marketplaces. The company was named by Forbes as one of America's Best Startup Employers in 2022. https://unstoppabledomains.com/

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Gelonghui Reports CMS’ Successful Phase III Study of Methylthioninium Chloride Enteric-coated Sustained-release Tablets

SHENZHEN, CHINA, Dec 20, 2022 – (ACN Newswire) – Gelonghui released a Press Release on “China Medical System Holdings Limited’s innovative product Methylthioninium Chloride Enteric-coated Sustained-release Tablets (‘the Product’) has obtained positive results for its Phase III clinical trial in China.”

This is another breakthrough for the Product after China Medical System Holdings Limited (“CMS” or the “Group”) had efficiently completed the enrollment of all 1,802 subjects for its China Phase III Clinical Trial in July this year, of which only 6 months (including the Spring Festival Holiday) was taken. The Group will actively move forward the Product’s new drug application (NDA) in China.

In this China Phase III clinical trial, Methylthioninium Chloride Enteric-coated Sustained-release Tablets was compared to placebo with the purpose of assessing its safety and efficacy in the improvement of histologically confirmed non-polypoid colorectal lesions in subjects undergoing screening or surveillance colonoscopy for colorectal cancer. The research was led by Beijing Friendship Hospital, Capital Medical University and conducted in 22 sites nationwide. In total, 1802 subjects were randomized, 897 in the Product arm and 905 in the placebo arm. Of those, 872 in the product arm and 879 in the placebo arm were in the primary efficacy population (FAS: Full Analysis Set).

The study met the primary endpoint with very high statistical significance:

in the overall FAS, the proportion of patients with at least one histologically confirmed non-polypoid colorectal lesion was significantly higher in the Product group (445/872 subjects; 51.0%) as compared with placebo (362/879, 41.2%); (adjusted OR [95% CI]: 1.55 [1.27, 1.89]; P< 0.0001).

The study also confirmed the superiority of the Product versus placebo in several clinically meaningful endpoints:

a) Number of histologically confirmed non-polypoid colorectal lesions per patient

In the FAS, the per patient number of histologically confirmed non-polypoid colorectal lesions in the Product group was 0.9, as compared to 0.7 in the placebo group (difference between groups [95%CI]: 0.18 [0.07，0.30] P=0.0022).

b) Number of histologically confirmed non-polypoid adenomas or cancers per patient

In the FAS, the per patient number of histologically confirmed non-polypoid adenomas or cancers in the Product group was 0.6 as compared to 0.5 in the placebo group (difference between groups [95%CI]: 0.12 ([0.03，0.22] P=0.0125).

c) Detection rate of non-polypoid adenoma or cancer (NP-ADR)

In the FAS, 341 out of 872 patients (39.1%) were detected with at least one histologically confirmed non-polypoid adenoma in the Product arm. as compared with 274 out of 879 patients in the placebo group (31.2%) (OR [95%CI]: 1.43 [1.17，1.75] P=0.0004).

d) Proportion of patients with at least one histologically confirmed <10 mm non-polypoid colorectal lesion

Non-polypoid histologically confirmed colorectal lesions less than <10 mm were found in 415 out of 872 patients (47.6%) in the Product group versus 350 out of 879 patients (39.8%) in the placebo group (OR [95%CI] 1.43 [1.17，1.74] P= 0.0003).

e) Number of histologically confirmed <10 mm non-polypoid colorectal lesions per patient

In the FAS, the per patient number of histologically confirmed non-polypoid colorectal lesions < 10 mm was 0.9 in the Product group versus 0.7 in the placebo group (difference between groups [95%CI]: 0.15 [0.03，0.26] P=0.0110).

f) Number of histologically confirmed non-polypoid adenomas or cancers <10 mm per patient

Overall, the per patient number of histologically confirmed non-polypoid adenomas or cancers <10 mm was 0.6 in the Product test group versus 0.5 in the placebo group (difference between groups [95 %CI]: 0.11 [0.02，0.20] P=0.0199).

No serious adverse events related to the drug were reported in this clinical study, and the product is well-tolerated with good safety.

Alessandro Della Chà, CEO of Cosmo Pharma, said: “We are very thankful to our partner CMS for this great clinical outcome, which is in line with our expectations and further confirms the data coming from our prior trial. The Product has proven once again its capacity of helping in particular the detection of the <10mm flat lesions, which are the most dangerous. We are thus very much looking forward to bring the Product in the Chinese market, which is the largest colonoscopy market of all“.

In an interview with Gelonghui, Mr. Yin, Director of Medical Department of CMS, said: “These excellent results showed that Product could enhance visualization of the colorectal lesions in subjects undergoing screening or surveillance colonoscopy, thus to help improve the detection rate of non-polypoid lesions, in order to reduce the mortality of colorectal cancer indirectly. We expect the Product will be marketed in the China soon, to potentially benefit tens of millions of people who get colonoscopies in China.“

About Methylthioninium Chloride Enteric-coated Sustained-release Tablets

Methylthioninium Chloride Enteric-coated Sustained-release Tablets is a novel oral formulation of the existing liquid colon staining dye methylene blues. Formulated by the proprietary MMX sustained-release technology of the Group’s partner Cosmo, it delivers the dye in a delayed and controlled way, distributing evenly through the full length of the colon, which enhances visualization of the colorectal lesions in subjects undergoing screening or surveillance colonoscopy, thus to help improve the detection rate of colorectal cancer/precancerous lesions.

About Gelonghui

Founded in 2014, Gelonghui is a leading global investment research platform in China. For the first time in China, it put forward the investment concept of “global vision, betting on China”, integrating financial media, research, investment banks, databases and other roles.

Media Contact
Address: Dachong International Center, Yuehai Street, Nanshan District, Shenzhen
Business Team, Gelonghui
Email: business@gelonghui.com
Tel: +86（0755）86533750
Website: https://www.gelonghui.com/

SOURCE: Gelonghui

Novotech is Gold Sponsor at Biotech Showcase 2023

SYDNEY, AU, Dec 20, 2022 – (ACN Newswire) – Novotech, the Asia Pacific centered biotech specialist CRO is proud to be Gold Sponsor at Biotech Showcase 2023. Novotech CEO Dr. John Moller and experts from the Novotech US and Asia Pacific teams will be attending the conference.

Meetings can be scheduled via the PartneringOne portal. https://informaconnect.com/biotech-showcase/partnering/

Novotech will share the Asia Pacific advantages for expedited clinical trials, where biotechs have access to Novotech's vast patient populations, strong local regulatory knowledge, extensive site and KOL networks, and reputation for data quality.

Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions in Asia Pacific delivering exclusive benefits for sponsors.

The latest industry research publication by GlobalData and Novotech found almost 50% of new trials globally have sites in Asia Pacific. According to the new publication titled "State of the Global Biotech Landscape: Where the Opportunities Lie", demand for Asia Pacific trial sites is strong with almost half of the more than 27,000 clinical trials initiated in 2021 having sites in Asia Pacific. The data shows almost 12,900 of the new trials had sites in Asia Pacific.

Download the report here https://novotech-cro.com/whitepapers/state-global-biotech-landscape-where-opportunities-lie

The report also noted that the Asia Pacific region, which has more than 6,772 trial sites each with access to an average of 2,136 million people, has considerable underutilized capacity presenting an opportunity for growth in multinational trials in the region.

Novotech this month was awarded the Frost & Sullivan Company of the Year Award 2022 for Best Practices in the Asia-Pacific contract research organization industry. Novotech has been a recipient of the Frost & Sullivan Asia Pacific Best Practices awards since 2006.

Frost & Sullivan said: "Our approach involves the deployment of best practices and strategic analytics across a value chain. Against this backdrop, Frost & Sullivan recognizes Novotech for its valuable achievement. Novotech addresses the global drug development market's unmet needs with a strong leadership focus that incorporates client-centric strategies with best-practice implementation. From feasibility assessments to regulatory submission support, data management, medical monitoring, and project management, the company provides a 360-degree approach to drug development for its biotech clients."

Novotech also recently produced a new publication for biotechs considering China for their clinical research, and the relevant processes required for global regulatory approvals. The report details regulatory requirements for biotechs including NDA and IND processes as well as ex-US research guidance for a successful US FDA approval pathway. Novotech provides the relevant regulatory knowledge and drug development pathways specifically designed to support the US FDA approval process, avoiding delays and additional costs.

Download whitepaper here https://novotech-cro.com/whitepapers/china-biotech-landscape-opportunities-china-and-path-usfda-approval

Novotech has also recently been benchmarked as a top 10 CRO among the world's leading CROs, is a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award.

About Novotech – https://novotech-cro.com

Novotech is internationally recognized as the leading Asia Pacific centred contract research organization (CRO) with global execution capabilities. Novotech is a clinical CRO with labs, phase I facilities, and drug development consulting services. It has accumulated experience in over 3,700 pre-clinical and clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biopharmaceutical clients conducting clinical trials in Asia, the US and globally. Novotech has over 2500 staff working across our offices in 13 geographies. For more information visit https://novotech-cro.com/contact

Media Contact
David James
E: communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

AustAsia Group in The Progress of IPO: One of The Top Five Dairy Farm Operators in China with Bright Future

HONG KONG, Dec 20, 2022 – (ACN Newswire) – Reproduced from Bloomberg Terminals, the dairy products increasingly become the daily necessities for the general public in the domestic market, especially in the era when the concern over health and nutrition is raised considerablely, and there are brand-new opportunities for the dairy industry to grow. On 16 December, AustAsia Group Ltd. ("AUSTASIA GROUP" or the "Company"; stock code: 2425.HK), a dairy farm operator, officially launched its IPO, which has now entered the third day. It is expected to be officially listed on the HKEx on 30th December, with China International Capital Corporation Hong Kong Securities Limited and DBS Asia Capital Limited as Joint Sponsors.

According to the prospectus, AUSTASIA GROUP is one of the top five dairy farm operators in China, ranking third, fourth and fifth among all dairy farm operators in China in terms of sales volume, sales value and production volume of raw milk in 2021. The Company has a diverse customer base, ranging from leading national and regional dairy product manufacturers to emerging dairy brands, and provides premium raw milk to its downstream dairy product manufacturer customers. Meanwhile, the Company is the first dairy farm operator in China to design, build and operate large-scale and standardised dairy farms with over 10,000 heads of dairy cows, according to Frost & Sullivan.

Benefiting from the rapid growth of dairy industry and establishing a leading position

As an essential people's livelihood industry, the dairy industry in China has been developing rapidly since the reform and opening up. Driven by the rapid development of the economy and the increase of per capita disposable income, the industry has experienced steady growth in recent years. According to Frost & Sullivan, the total retail sales value of dairy products is expected to increase from RMB557.4 billion in 2021 to RMB875.5 billion in 2026 at a CAGR of 9.5%. Also, the rapid growth and structural changes in the downstream dairy landscape have increased the demand for high-end raw milk in the upstream market, and the industry has a broad development prospect.

Leveraging plentiful experience and expertise, AUSTASIA GROUP commenced its dairy farming operations in China in 2009, laying a solid foundation for its long-term development. AUSTASIA GROUP currently owns and operates ten large-scale dairy farms in China, with an aggregate gross land area of approximately 14,657 mu. As of 30 June 2022, the total herd size of dairy cows was 111,424 heads, of which 57,383 were milkable cows. From 2019 to 2021 and for the six months ended 30 June 2022, the Company produced approximately 565,400 tons, 582,800 tons, 638,800 tons and 359,200 tons of raw milk, making it a pioneer in the high-growth dairy sector.

Proven and synergistic business integration with strong and stable financial performance

Relying on its strong and comprehensive competitiveness, AUSTASIA GROUP has established two main business segments, namely raw milk business and beef cattle business, and has achieved synergy between these two segments. The raw milk business provides stable and self-sustaining source of beef cattle with excellent genetic traits, health conditions and easy traceability for its beef cattle business, which improves the productivity of beef cattle and promoting a virtuous circle of development. Meanwhile, AUSTASIA GROUP also sells in-house branded dairy products under its own brand "AustAsia" to large coffee shops, milk tea shops, bakeries and dim sum chains in China.

At present, AUSTASIA GROUP owns and operates two large-scale beef cattle feedlots in China. The Company had a total 28,152 heads of beef cattle as of 30 June 2022. In addition, the business of AUSTASIA GROUP spans the key stages of the dairy farming value chain, including farm design and management, forage cultivation, in-house feed production, dairy cow breeding and raw milk production. Such highly proven and synergetic business integration model has built a moat for the development of the enterprise.

With its integrated business model, AUSTASIA GROUP recorded strong and stable operating income. According to the prospectus, the Company's revenue from continuing operations increased from US$352 million in 2019 to US$522 million in 2021, representing a CAGR of 21.9%. As of 30 June 2022, the revenue amounted to US$278 million, with a year-on-year growth of 15.4%. From 2019 to 2021 and for the six months ended 30 June 2022, the gross profit margin of the Company was 34.6%, 37.1%, 33.7% and 24.5% respectively, and the adjusted net profit margin for the same period was 21.5%, 25.7%, 23.1% and 14.8% respectively.

At present, the dairy industry is in the stage of accelerated development, and high-quality dairy enterprises that can provide high-quality and high nutrition for the market are expected to usher in a golden period of growth. AUSTASIA GROUP, which is in the process of IPO, has made full preparations for listing on the Hong Kong Stock Exchange. In the future, the Company will continue to develop beef cattle business, expand diversified customer base, and develop genetic breeding technology, so as to create greater long-term value in a responsible and sustainable way, and step onto a new level of development.

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

#WBSBangkok wraps up a successful two days and breaks new grounds for web3 in 2023

#WBSBangkok set the global web3 stage, as hundreds of industry trailblazers, thought leaders, high-net-worth investors, global media, and blockchain technologists converged together in Bangkok on 8-9 December 2022.

BANGKOK, Thailand, Dec 19, 2022 – (ACN Newswire) – The 23rd edition of World Blockchain Summit – Bangkok 2022, hosted a diverse crowd of web3 enthusiasts, industry leaders, and technology pioneers all under one roof, to inspire and stimulate business opportunities through mutually beneficial collaborations across the ASEAN region. The two-day summit registered over 600+ attendees and was an ultimate meeting point for the global and local Thai web3 community.

#WBSBangkok put together an incredible lineup of innovators and speakers making remarkable contributions to digital transformation in various sectors. Top speakers for the summit included Jirayut Srupsrisopa, Founder and Group CEO at Bitkub Capital Group Holdings Co., Ltd; Matt Sorg, Head of Technology at Solana Foundation; Daniel Oon, Head of Defi at Algorand Foundation and Jon Russell, Partner at Crypto.com to name a few.

Nicole Nguyen – “Bangkok and WBS have always been at the heart of the web3 movement in APAC and as Asia’s leading web3 community, APAC DAO is keen to network with and explore potential collaboration with global partners and business leaders to become a prominent launchpad for web3 builders in the region.” (to be replaced)

Cris Tran – “After a great turnout in Dubai, can’t wait to be back in Thailand for our BKK Edition. Southeast Asia is truly the most vibrant place for blockchain and crypto development” (to be replaced)

During the 2-day summit, blockchain solution providers, web3 projects, investment partners, and community partners showcased their offerings and were able to network and meet with qualified investors, buyers, and other stakeholders to promote their offerings and solutions.

The World Blockchain Summit – Bangkok 2022, also provided startups with a platform to exhibit their innovative capabilities in front of global investors at the Startup World Cup Pitch Competition. (Winner to be added here) a company providing an ultimate playground for creative minds and virtual adventurers was declared a winner.

“A wonderful fusion of Web3 architects thought leaders, regulators, and users made #WBSBangkok one of the best places to experience and discover the latest trends in the blockchain world. As we wrap up 2022 with #WBSBangkok, we are excited to see what’s in store for web3 in 2023,” stated Mohammed Saleem, Founding Chairman, of the World Blockchain Summit (WBS).

World Blockchain Summit will begin another bright year with its next grand edition in Dubai, bringing together MENA’s leading players in the space in March 2023.

World Blockchain Summit Bangkok is sponsored by-

Headline Sponsor: Bybit
Platinum Sponsor: SafuuX; Xapo Bank; SUPEREX
Gold Sponsor: Pandolab; Shipfinex; Undeads.com
Silver Sponsor: Lollipop; io
Strategic Partner: Solana Foundation
Lunch Sponsor: SafuuX
Lanyard Sponsor: GBR Coin
Community Partner: Women In Blockchain Asia
Pitch Partners : Aura Dogs; Gawooni Metalabs; Isekaiverse
Exhibitor : Amaze World; Shellboxes; Riva Metaverse; Oceanmoney; COINWEB

Official Media Partner: Coin Edition

Official PR Partner: Luna PR

Media Partners:

About World Blockchain Summit (WBS)

WBS hosts a global series of blockchain, crypto, metaverse and web3 business platforms that bring together the ecosystem of founders, developers, investors, regulators, enterprise buyers and influencers.

As the world’s largest blockchain and web3 summit series, WBS has hosted more than 35,000 industry stakeholders at more than 20 editions in 10+ destinations around the world.

In collaboration with key industry stakeholders and our advisory board members, WBS curates a regionally relevant agenda for each edition that highlights the latest trends and upcoming opportunities in the market while also enabling deal flow, business development and more for our community of founders and investors.

WBS is committed to boosting the development, adoption, and growth of the entire web3 ecosystem.

Contact: comms@worldblockchainsummit.com

Music Licensing, Inc. (OTC: SONG) Announces Major Updates for Investors: Form 211 Filing, Potential Forward Stock Split or Dividend, and Plans to List on Nasdaq

NAPLES, FL, Dec 19, 2022 – (ACN Newswire) – Music Licensing, Inc. (OTC PINK:SONG), owner of Pro Music Rights, one of the world's largest music licensing companies, is pleased to announce that a new Form 211 has been filed with FINRA to restore its proprietary quote eligibility. The company is now awaiting FINRA to process the form and is confident that it will fully restore its eligibility.

In addition, Music Licensing, Inc. (OTC: SONG) is exploring a forward stock split or a stock-based dividend once FINRA has processed the new Form 211. The company is considering a 1 for 5 forward stock split to increase liquidity, tighten the bid/ask spread, and increase trading volume. It is also exploring the possibility of issuing a dividend to shareholders in the form of a new class of common stock with identical rights as the current class. Music Licensing, Inc. (OTC: SONG) plans to file another Form 211 with FINRA to allow both classes of common stock to be publicly traded.

Music Licensing, Inc. (OTC: SONG) has been in communication with Nasdaq's First North Growth Market in Sweden to list on the exchange. On December 15, 2022, the company's European capital markets listing advisor, DCM Asesores, had a call with Nasdaq First North Growth Market to become a certified adviser. DCM Asesores expects to undergo training to become a certified adviser by mid to late February 2023 and guide Music Licensing, Inc. (OTC: SONG) through the listing process on Nasdaq First North Growth Market. Nasdaq has already confirmed the reservation of the symbol NASDAQ: MUSIC for Music Licensing, Inc. (OTC: SONG)'s listing.

In other news, Music Licensing, Inc. (OTC: SONG) is working with its legal counsel to collect on a judgment won against Ayujoy Herbals (OTC: AJOY) and expects to receive a response on an arbitration complaint filed with FINRA by Pro Music Rights and the Jake P. Noch Family Office seeking $386,574,108.25 plus interest and costs from OTC Link LLC by January 6, 2023.

About Pro Music Rights, Inc. (ProMusicRights.com)

Pro Music Rights the 5th public performance rights organization (PRO) ever formed in the United States. Its licensees include notable companies like TikTok, iHeart Media, Triller, Napster, 7Digital, Vevo, and hundreds of others. Pro Music Rights controls an estimated market share of 7.4% in the United States, representing over 2,500,000 works that feature notable artists such as A$AP Rocky, Wiz Khalifa, Pharrell, Young Jeezy, Juelz Santana, Lil Yachty, MoneyBaggYo, Larry June, Trae Pound, Sause Walka, Trae Tha Truth, Sosamann, Soulja Boy, Lex Luger, Lud Foe, SlowBucks, Gunplay, OG Maco, Rich The Kid, Fat Trel, Young Scooter, Nipsey Hussle, Famous Dex, Boosie Badazz, Shy Glizzy, 2 Chainz, Migos, Gucci Mane, Young Dolph, Trinidad James, Fall Out Boy, and countless others. For more information, please visit promusicrights.com.

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that, all forward-looking statements involve risks and uncertainties, including without limitation, the ability of Music Licensing, Inc. & Pro Music Rights, Inc. to accomplish its stated plan of business. Music Licensing, Inc. & Pro Music Rights, Inc. believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by Pro Music Rights, Inc., Music Licensing, Inc., or any other person.

Contact:
investors@ProMusicRights.com

SOURCE: Music Licensing, Inc.

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Gelonghui Reports CMS’ Successful Phase III Study of Methylthioninium Chloride Enteric-coated Sustained-release Tablets

SHENZHEN, CHINA, Dec 19, 2022 – (ACN Newswire) – Gelonghui released a Press Release on "China Medical System Holdings Limited's innovative product Methylthioninium Chloride Enteric-coated Sustained-release Tablets ('the Product') has obtained positive results for its Phase III clinical trial in China."

This is another breakthrough for the Product after China Medical System Holdings Limited ("CMS" or the "Group") had efficiently completed the enrollment of all 1,802 subjects for its China Phase III Clinical Trial in July this year, of which only 6 months (including the Spring Festival Holiday) was taken. The Group will actively move forward the Product's new drug application (NDA) in China.

In this China Phase III clinical trial, Methylthioninium Chloride Enteric-coated Sustained-release Tablets was compared to placebo with the purpose of assessing its safety and efficacy in the improvement of histologically confirmed non-polypoid colorectal lesions in subjects undergoing screening or surveillance colonoscopy for colorectal cancer. The research was led by Beijing Friendship Hospital, Capital Medical University and conducted in 22 sites nationwide. In total, 1802 subjects were randomized, 897 in the Product arm and 905 in the placebo arm. Of those, 872 in the product arm and 879 in the placebo arm were in the primary efficacy population (FAS: Full Analysis Set).

The study met the primary endpoint with very high statistical significance:

In the overall FAS, the proportion of patients with at least one histologically confirmed non-polypoid colorectal lesion was significantly higher in the Product group (445/872 subjects; 51.0%) as compared with placebo (362/879, 41.2%); (adjusted OR [95% CI]: 1.55 [1.27, 1.89]; P< 0.0001).

The study also confirmed the superiority of the Product versus placebo in several clinically meaningful endpoints:

a) Number of histologically confirmed non-polypoid colorectal lesions per patient
In the FAS, the per patient number of histologically confirmed non-polypoid colorectal lesions in the Product group was 0.9, as compared to 0.7 in the placebo group (difference between groups [95%CI]: 0.18 [0.07, 0.30] P=0.0022).

b) Number of histologically confirmed non-polypoid adenomas or cancers per patient
In the FAS, the per patient number of histologically confirmed non-polypoid adenomas or cancers in the Product group was 0.6 as compared to 0.5 in the placebo group (difference between groups [95%CI]: 0.12 ([0.03, 0.22] P=0.0125).

c) Detection rate of non-polypoid adenoma or cancer (NP-ADR)
In the FAS, 341 out of 872 patients (39.1%) were detected with at least one histologically confirmed non-polypoid adenoma in the Product arm. as compared with 274 out of 879 patients in the placebo group (31.2%) (OR [95%CI]: 1.43 [1.17, 1.75] P=0.0004).

d) Proportion of patients with at least one histologically confirmed <10 mm non-polypoid colorectal lesion
Non-polypoid histologically confirmed colorectal lesions less than <10 mm were found in 415 out of 872 patients (47.6%) in the Product group versus 350 out of 879 patients (39.8%) in the placebo group (OR [95%CI] 1.43 [1.17, 1.74] P= 0.0003).

e) Number of histologically confirmed <10 mm non-polypoid colorectal lesions per patient
In the FAS, the per patient number of histologically confirmed non-polypoid colorectal lesions < 10 mm was 0.9 in the Product group versus 0.7 in the placebo group (difference between groups [95%CI]: 0.15 [0.03, 0.26] P=0.0110).

f) Number of histologically confirmed non-polypoid adenomas or cancers <10 mm per patient
Overall, the per patient number of histologically confirmed non-polypoid adenomas or cancers <10 mm was 0.6 in the Product test group versus 0.5 in the placebo group (difference between groups 95 %CI]: 0.11 [0.02, 0.20] P=0.0199).

No serious adverse events related to the drug were reported in this clinical study, and the product is well-tolerated with good safety.

Alessandro Della Cha, CEO of Cosmo Pharma, said: "We are very thankful to our partner CMS for this great clinical outcome, which is in line with our expectations and further confirms the data coming from our prior trial. The Product has proven once again its capacity of helping in particular the detection of the <10mm flat lesions, which are the most dangerous. We are thus very much looking forward to bring the Product in the Chinese market, which is the largest colonoscopy market of all".

In an interview with Gelonghui, Mr. Yin, Director of Medical Department of CMS, said: "These excellent results showed that Product could enhance visualization of the colorectal lesions in subjects undergoing screening or surveillance colonoscopy, thus to help improve the detection rate of non-polypoid lesions, in order to reduce the mortality of colorectal cancer indirectly. We expect the Product will be marketed in the China soon, to potentially benefit tens of millions of people who get colonoscopies in China."

About Methylthioninium Chloride Enteric-coated Sustained-release Tablets

Methylthioninium Chloride Enteric-coated Sustained-release Tablets is a novel oral formulation of the existing liquid colon staining dye methylene blues. Formulated by the proprietary MMX sustained-release technology of the Group's partner Cosmo, it delivers the dye in a delayed and controlled way, distributing evenly through the full length of the colon, which enhances visualization of the colorectal lesions in subjects undergoing screening or surveillance colonoscopy, thus to help improve the detection rate of colorectal cancer/precancerous lesions.

About Gelonghui

Founded in 2014, Gelonghui is a leading global investment research platform in China. For the first time in China, it put forward the investment concept of "global vision, betting on China", integrating financial media, research, investment banks, databases and other roles.

Media Contact
Address: Dachong International Center, Yuehai Street, Nanshan District, Shenzhen
Business Team, Gelonghui
Email: business@gelonghui.com
Tele: +86 (0755) 86533750
Website: https://www.gelonghui.com/

SOURCE: Gelonghui

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Samaiden Group Signs Agreement to Explore Cambodia Venture

PETALING JAYA, Malaysia, Dec 19, 2022 – (ACN Newswire) – Samaiden Group Berhad (Bursa: SAMAIDEN, 0223), a clean energy solution specialist principally involved in engineering, procurement, construction, and commissioning (EPCC) of solar photovoltaic (PV) systems and power, is pleased to announce that the Group's wholly-owned subsidiary, Samaiden Sdn Bhd, has signed a partnership agreement with Management Venture Asia (Cambodia) Ltd. (MVA) today, to explore the clean energy-related business opportunities in Cambodia.

Group Managing Director of Samaiden, Ir. Chow Pui Hee

Director of MVA, H.E. Salah Essa

MVA, a business consultancy and clean energy project developer based in Phnom Penh, Cambodia is primarily engaged in facilitating business ventures and taking products to market and market research throughout Asia. The company has successfully completed the development of 20MW ground mounted solar project in Bavet, in which the project was awarded power purchase agreement by the Electricite du Cambodge in August 2019.

Group Managing Director of Samaiden, Ir. Chow Pui Hee said, "We're looking forward to the collaboration with MVA given their strong presence in Cambodia. Expanding in Southeast Asia is part of our 5-years plan given the region's growing population and its geographical advantages."

"We firmly believe the partnership with MVA will ensure our expansion plans in Cambodia are focused. We are honoured to have MVA as our business partner in the development of clean energy in the country given its vast experiences and network in clean energy infrastructure.

The Director of MVA, H.E. Salah Essa quotes, "We are looking forward to this collaboration with Samaiden in the renewable and sustainable energy businesses in Cambodia and hope to draw on their industry experience and skills to make this venture successful for nation growth and aligning with country goal towards Net Zero Carbon policy 2050."

Samaiden Group Berhad: 0223 [BURSA: SAMAIDEN], https://samaiden.com.my/

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com